ALLMedicine™ Advanced Prostate Cancer Center
Research & Reviews 1,248 results
https://doi.org/10.1097/CAD.0000000000001251
Anti-cancer Drugs; Lu M, Xu Z et. al.
Sep 26th, 2021 - Sperm-associated antigen 9 (SPAG9) is closely related to the growth and metastasis of advanced prostate cancer. Docetaxel (DTX) is the gold standard for chemotherapy of prostate cancer, but its side effects decrease the life quality of patients. T...
https://doi.org/10.1038/s41391-021-00439-9 10.1200/JCO.2009.26.0133 10.1111/j.1464-410X.2006.06260.x 10.1111/j.1464-410X.2011.10760.x 10.2105/AJPH.91.1.126 10.1002/bjs.6930 10.1503/cmaj.101715 10.1177/1536867X0200200102 10.1002/sim.1970 10.5213/inj.1632722.361 10.1200/JCO.2014.55.1531 10.1016/j.ejca.2019.04.031 10.7326/0003-4819-158-10-201305210-00005 10.1038/pcan.2012.21 10.1007/s11606-014-3171-8 10.1016/S0140-6736(13)61215-5 10.1016/j.clon.2019.12.008 10.1016/S1470-2045(18)30646-6 10.1016/j.ctrv.2014.12.010 10.1093/pubmed/fdr051 10.1093/pubmed/fdr054
Prostate Cancer and Prostatic Diseases; Parry MG, Boyle JM et. al.
Sep 9th, 2021 - Many factors are implicated in the potential 'under-treatment' of prostate cancer but little is known about the between-hospital variation. The National Prostate Cancer Audit (NPCA) database was used to identify high-risk localised or locally adva...
https://doi.org/10.1007/s10147-021-02023-6 10.1007/s00345-008-0250-7 10.1016/j.brachy.2017.01.006 10.1016/j.ijrobp.2016.12.013 10.1016/j.radonc.2012.01.007 10.1016/j.ijrobp.2020.11.008 10.1016/j.radonc.2018.10.013 10.1016/j.radonc.2017.12.025 10.21873/anticanres.13137 10.1111/iju.14305 10.3390/cancers13081856 10.1016/j.eururo.2020.09.042 10.1007/s11604-020-01023-2 10.1016/j.ijrobp.2008.04.038 10.1016/j.ijrobp.2006.04.029 10.1016/s1470-2045(10)70223-0 10.1200/JCO.2007.13.9881 10.1200/JCO.2007.14.9021 10.1016/j.eururo.2016.03.021 10.1002/cncr.33034 10.1016/s0360-3016(01)02664-5 10.1016/s0360-3016(98)00438-6 10.1016/j.radonc.2014.07.013 10.1016/j.ctrv.2016.03.016 10.1016/j.ijrobp.2012.08.036 10.1016/j.radonc.2008.11.013 10.1093/jrr/rrt128
International Journal of Clinical Oncology; Makino T, Sakurai T et. al.
Sep 9th, 2021 - No standard treatment exists for locally advanced prostate cancer (PC). This study evaluated the long-term treatment outcomes and toxicity in patients with clinically locally advanced and/or lymph node (LN)-positive PC who underwent high-dose-rate...
https://doi.org/10.21873/anticanres.15252
Anticancer Research; Masuda H, Fujimoto A et. al.
Sep 4th, 2021 - Androgen deprivation therapy (ADT) is one of the most effective treatments for advanced prostate cancer (PCa). However, it has been reported that the use of ADT is significantly associated with an increased risk of acute kidney injury (AKI) among ...
https://doi.org/10.2967/jnumed.121.262528
Journal of Nuclear Medicine : Official Publication, Socie... Seifert R, Sandach P et. al.
Aug 28th, 2021 - Background: Molecular tumor volume (MTV) is a parameter of interest in advanced prostate cancer for assessing total disease burden on prostate specific membrane antigen (PSMA) PET. Although software segmentation tools can delineate whole-body MTV,...
Guidelines 7 results
https://doi.org/10.1016/j.prro.2020.10.002
Practical Radiation Oncology; Zietman AL,
Dec 15th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|
https://doi.org/10.1097/JU.0000000000001376
The Journal of Urology; Lowrance WT, Breau RH et. al.
Sep 23rd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...
https://doi.org/10.1097/JU.0000000000001375
The Journal of Urology; Lowrance WT, Breau RH et. al.
Sep 23rd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB
Sep 7th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|
https://doi.org/10.1002/pros.24053
The Prostate REFERENCES; Shore ND, Drake CG et. al.
Aug 12th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...
Drugs 9 results see all →
News 217 results
https://www.medscape.com/viewarticle/955117
Jul 21st, 2021 - (Reuters Health) - Several therapies commonly used to treat men with metastatic castration-resistant prostate cancer don't appear to cause a significant decline in cognitive function, a small study suggests. Researchers examined data on 155 men 65...
https://www.medscape.com/viewarticle/954899
Jul 16th, 2021 - The Institute of Cancer Research (ICR) has expressed disappointment at the decision by The National Institute for Health and Care Excellence (NICE) not to approve abiraterone as a first-line treatment for newly diagnosed, advanced prostate cancer....
https://www.medscape.com/viewarticle/952659
Jun 8th, 2021 - The National Institute for Health and Care Excellence (NICE) has published draft guidance on the use of the androgen receptor inhibitor enzalutamide (Xtandi, Astellas), plus androgen deprivation therapy (ADT), as an option for treating prostate ca...
https://www.medscape.com/viewarticle/946111
Feb 19th, 2021 - The results of a trial led by Medical Detection Dogs in Milton Keynes suggest that trained dogs can detect advanced prostate cancer in urine samples with high specificity and sensitivity. The study, published in PLoS One, tested the clinical fea...
https://www.medscape.com/viewarticle/945995
Feb 18th, 2021 - (Reuters Health) - Daily relugolix therapy cuts menstrual bleeding by at least half without affecting bone density in 71% of women with uterine fibroids, according to results from the LIBERTY 2 trial, published by The New England Journal of Medici...
